NASDAQ · AZTA
Healthcare · Medical - Instruments & Supplies
$39.35
Down-$3.38 (-7.91%)
Updated Oct 7, 2026, 8:47 AM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AZTA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AZTA closed at $39.35 after 21 trading sessions, up 27.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $43.755 | $46.41 | $39.33 | $39.35 | 2.55M |
| Oct 5, 2026 | $39.49 | $43.215 | $38.835 | $42.73 | 2.37M |
| Oct 2, 2026 | $35.05 | $41.995 | $34.66 | $38.75 | 3.38M |
| Oct 1, 2026 | $34.92 | $35.03 | $34.19 | $34.48 | 935.98K |
| Sep 30, 2026 | $34.37 | $35.24 | $34.14 | $34.89 | 929.06K |
| Sep 29, 2026 | $34.21 | $34.45 | $33.66 | $34.28 | 813.91K |
| Sep 28, 2026 | $33.58 | $34.71 | $33.281 | $34.25 | 736.98K |
| Sep 25, 2026 | $34.36 | $34.39 | $33.67 | $34.02 | 781.1K |
| Sep 24, 2026 | $33.69 | $34.8225 | $33.51 | $34.20 | 917.8K |
| Sep 23, 2026 | $34.15 | $34.88 | $33.88 | $34.09 | 769.26K |
| Sep 22, 2026 | $34.00 | $34.855 | $33.72 | $34.28 | 1.13M |
| Sep 21, 2026 | $33.53 | $33.97 | $33.10 | $33.75 | 718.18K |
| Sep 18, 2026 | $33.44 | $33.82 | $33.03 | $33.24 | 1.43M |
| Sep 17, 2026 | $33.94 | $34.035 | $33.37 | $33.63 | 750.81K |
| Sep 16, 2026 | $33.03 | $33.93 | $32.98 | $33.21 | 729.67K |
| Sep 15, 2026 | $31.93 | $33.82 | $31.93 | $33.03 | 718.49K |
| Sep 14, 2026 | $30.88 | $32.28 | $30.27 | $32.04 | 688.78K |
| Sep 11, 2026 | $30.56 | $31.075 | $30.175 | $30.85 | 748.61K |
| Sep 10, 2026 | $29.74 | $30.38 | $29.64 | $30.18 | 853.75K |
| Sep 9, 2026 | $30.57 | $30.72 | $30.06 | $30.15 | 879.59K |
| Sep 8, 2026 | $30.82 | $31.655 | $30.655 | $30.82 | 1.16M |
The latest Smart Investors Daily articles mentioning AZTA.
Company
Market Activity
Research & News
AZTA research
Company profile and research snapshot.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | Needham | Buy | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Needham | Buy | — |
| May 6, 2026 | Needham | Buy | — |
| Apr 6, 2026 | Evercore ISI Group | Outperform | — |
Generated Oct 6, 2026, 9:03 PM
Azenta, Inc. (AZTA) is down $3.38 or 7.91% today, marking a significant decline without a clear catalyst directly linked to the company. The broader market appears to be experiencing sector rotation, with other companies like Apogee Enterprises and Constellation Energy gaining attention on positive earnings results.
Bottom line: AZTA's 7.91% decline appears driven by broader market rotation toward other outperforming stocks rather than company-specific bad news. Investors should look for upcoming earnings reports and company developments to assess whether this is a buying opportunity or a sign of deeper concerns about AZTA's competitive position and growth trajectory.
Yahoo · Sep 14, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.
Benzinga · Sep 14, 2026
Needham analyst David Saxon reiterates Azenta (NASDAQ:AZTA) with a Buy and maintains $37 price target.
Yahoo · Sep 4, 2026
Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l.
Yahoo · Sep 1, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AZTA.
